vs
Idexx Laboratories（IDXX）とADVANCED DRAINAGE SYSTEMS, INC.（WMS）の財務データ比較。上の社名をクリックして会社を切り替えられます
Idexx Laboratoriesの直近四半期売上が大きい（$1.1B vs $693.4M、ADVANCED DRAINAGE SYSTEMS, INC.の約1.6倍）。Idexx Laboratoriesの純利益率が高く（22.8% vs 13.5%、差は9.3%）。Idexx Laboratoriesの前年同期比売上増加率が高い（14.3% vs 0.4%）。Idexx Laboratoriesの直近四半期フリーキャッシュフローが多い（$326.3M vs $183.6M）。過去8四半期でIdexx Laboratoriesの売上複合成長率が高い（6.4% vs 3.0%）
IDEXXラボラトリーズは1983年設立の米国多国籍企業で、伴侶動物獣医療、家畜・家禽、水質検査、乳製品分野向けの製品・サービスの開発・製造・流通を手がけています。本社はメイン州ウェストブルックにあり、EMEA地域の拠点はオランダのホーフドルプに置かれています。
アドバンスド・ドレネージ・システムズ（略称ADS）は米国の企業で、ポリプロピレン・ポリエチレン製パイプ、プラスチック製浸出場システム、浄化槽と付属部品、雨水調整施設、PVC製排水構造物、継手、水ろ過・分離装置の設計・製造・販売を行い、米国最大の高密度ポリエチレンパイプメーカーです。本社はオハイオ州ヒリアードに所在します。
IDXX vs WMS — 直接比較
損益計算書 — Q4 FY2025 vs Q3 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $1.1B | $693.4M |
| 純利益 | $248.2M | $93.6M |
| 粗利率 | 60.3% | 37.4% |
| 営業利益率 | 28.9% | 19.7% |
| 純利益率 | 22.8% | 13.5% |
| 売上前年比 | 14.3% | 0.4% |
| 純利益前年比 | 14.8% | 15.3% |
| EPS（希薄化後） | $3.09 | $1.19 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $1.1B | $693.4M | ||
| Q3 25 | $1.1B | $850.4M | ||
| Q2 25 | $1.1B | $829.9M | ||
| Q1 25 | $998.4M | $615.8M | ||
| Q4 24 | $954.3M | $690.5M | ||
| Q3 24 | $975.5M | $782.6M | ||
| Q2 24 | $1.0B | $815.3M | ||
| Q1 24 | $964.1M | $653.8M |
| Q4 25 | $248.2M | $93.6M | ||
| Q3 25 | $274.6M | $156.0M | ||
| Q2 25 | $294.0M | $143.9M | ||
| Q1 25 | $242.7M | $77.2M | ||
| Q4 24 | $216.1M | $81.2M | ||
| Q3 24 | $232.8M | $130.4M | ||
| Q2 24 | $203.3M | $161.4M | ||
| Q1 24 | $235.6M | $94.8M |
| Q4 25 | 60.3% | 37.4% | ||
| Q3 25 | 61.8% | 40.0% | ||
| Q2 25 | 62.6% | 39.8% | ||
| Q1 25 | 62.4% | 36.7% | ||
| Q4 24 | 59.8% | 35.0% | ||
| Q3 24 | 61.1% | 37.6% | ||
| Q2 24 | 61.7% | 40.8% | ||
| Q1 24 | 61.5% | 38.5% |
| Q4 25 | 28.9% | 19.7% | ||
| Q3 25 | 32.1% | 26.3% | ||
| Q2 25 | 33.6% | 24.8% | ||
| Q1 25 | 31.7% | 19.0% | ||
| Q4 24 | 27.4% | 18.4% | ||
| Q3 24 | 31.2% | 23.9% | ||
| Q2 24 | 26.3% | 27.7% | ||
| Q1 24 | 31.0% | 20.7% |
| Q4 25 | 22.8% | 13.5% | ||
| Q3 25 | 24.8% | 18.3% | ||
| Q2 25 | 26.5% | 17.3% | ||
| Q1 25 | 24.3% | 12.5% | ||
| Q4 24 | 22.7% | 11.8% | ||
| Q3 24 | 23.9% | 16.7% | ||
| Q2 24 | 20.3% | 19.8% | ||
| Q1 24 | 24.4% | 14.5% |
| Q4 25 | $3.09 | $1.19 | ||
| Q3 25 | $3.40 | $1.99 | ||
| Q2 25 | $3.63 | $1.84 | ||
| Q1 25 | $2.96 | $0.99 | ||
| Q4 24 | $2.62 | $1.04 | ||
| Q3 24 | $2.80 | $1.67 | ||
| Q2 24 | $2.44 | $2.06 | ||
| Q1 24 | $2.81 | $1.22 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $180.1M | $1.0B |
| 総負債低いほど良い | $450.0M | — |
| 株主資本純資産 | $1.6B | $1.9B |
| 総資産 | $3.4B | $4.1B |
| 負債/資本比率低いほどレバレッジが低い | 0.28× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $180.1M | $1.0B | ||
| Q3 25 | $208.2M | $812.9M | ||
| Q2 25 | $164.6M | $638.3M | ||
| Q1 25 | $164.0M | $463.3M | ||
| Q4 24 | $288.3M | $488.9M | ||
| Q3 24 | $308.6M | $613.0M | ||
| Q2 24 | $401.6M | $541.6M | ||
| Q1 24 | $397.4M | $490.2M |
| Q4 25 | $450.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | $617.8M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $1.3B |
| Q4 25 | $1.6B | $1.9B | ||
| Q3 25 | $1.6B | $1.8B | ||
| Q2 25 | $1.5B | $1.7B | ||
| Q1 25 | $1.4B | $1.5B | ||
| Q4 24 | $1.6B | $1.5B | ||
| Q3 24 | $1.6B | $1.4B | ||
| Q2 24 | $1.6B | $1.3B | ||
| Q1 24 | $1.6B | $1.2B |
| Q4 25 | $3.4B | $4.1B | ||
| Q3 25 | $3.4B | $4.1B | ||
| Q2 25 | $3.3B | $3.9B | ||
| Q1 25 | $3.2B | $3.7B | ||
| Q4 24 | $3.3B | $3.6B | ||
| Q3 24 | $3.4B | $3.5B | ||
| Q2 24 | $3.4B | $3.4B | ||
| Q1 24 | $3.4B | $3.3B |
| Q4 25 | 0.28× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.83× | ||
| Q4 24 | 0.39× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 1.11× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $355.8M | $269.3M |
| フリーキャッシュフロー営業CF - 設備投資 | $326.3M | $183.6M |
| FCFマージンFCF / 売上 | 29.9% | 26.5% |
| 設備投資強度設備投資 / 売上 | 2.7% | 12.4% |
| キャッシュ転換率営業CF / 純利益 | 1.43× | 2.88× |
| 直近12ヶ月FCF直近4四半期 | $1.1B | $577.1M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $355.8M | $269.3M | ||
| Q3 25 | $402.3M | $234.9M | ||
| Q2 25 | $185.7M | $275.0M | ||
| Q1 25 | $238.0M | $41.2M | ||
| Q4 24 | $262.0M | $189.9M | ||
| Q3 24 | $220.1M | $166.9M | ||
| Q2 24 | $248.3M | $183.4M | ||
| Q1 24 | $198.6M | $17.7M |
| Q4 25 | $326.3M | $183.6M | ||
| Q3 25 | $371.2M | $176.4M | ||
| Q2 25 | $151.6M | $222.4M | ||
| Q1 25 | $207.9M | $-5.3M | ||
| Q4 24 | $232.8M | $135.7M | ||
| Q3 24 | $192.0M | $112.4M | ||
| Q2 24 | $215.0M | $125.7M | ||
| Q1 24 | $168.3M | $-29.8M |
| Q4 25 | 29.9% | 26.5% | ||
| Q3 25 | 33.6% | 20.7% | ||
| Q2 25 | 13.7% | 26.8% | ||
| Q1 25 | 20.8% | -0.9% | ||
| Q4 24 | 24.4% | 19.7% | ||
| Q3 24 | 19.7% | 14.4% | ||
| Q2 24 | 21.4% | 15.4% | ||
| Q1 24 | 17.5% | -4.6% |
| Q4 25 | 2.7% | 12.4% | ||
| Q3 25 | 2.8% | 6.9% | ||
| Q2 25 | 3.1% | 6.3% | ||
| Q1 25 | 3.0% | 7.6% | ||
| Q4 24 | 3.1% | 7.9% | ||
| Q3 24 | 2.9% | 7.0% | ||
| Q2 24 | 3.3% | 7.1% | ||
| Q1 24 | 3.1% | 7.3% |
| Q4 25 | 1.43× | 2.88× | ||
| Q3 25 | 1.47× | 1.51× | ||
| Q2 25 | 0.63× | 1.91× | ||
| Q1 25 | 0.98× | 0.53× | ||
| Q4 24 | 1.21× | 2.34× | ||
| Q3 24 | 0.95× | 1.28× | ||
| Q2 24 | 1.22× | 1.14× | ||
| Q1 24 | 0.84× | 0.19× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
IDXX
| Vet Lab Consumables | $389.0M | 36% |
| Reference Laboratory Diagnostic And Consulting Services | $349.2M | 32% |
| Rapid Assay Products | $76.0M | 7% |
| Recurring Revenue | $70.6M | 6% |
| CAG Diagnostic Capital Instruments | $58.1M | 5% |
| Water Segment | $50.5M | 5% |
| Livestock And Poultry Diagnostics Segment | $37.5M | 3% |
| CAG Diagnostics Service And Accessories | $35.3M | 3% |
| Systems And Hardware | $20.1M | 2% |
| Rebate And Up Front Considerations Arrangements | $2.4M | 0% |
| Extended Warranties And Post Contract Support Revenue | $1.0M | 0% |
WMS
| Reportable Segment Aggregation Before Other Operating Segment | $557.3M | 80% |
| Other | $85.5M | 12% |
| Pipe | $35.5M | 5% |
| Allied Products And Other | $15.0M | 2% |
